SEVEN BRIDGES GENOMICS (VELSERA)

Company Overview

Seven Bridges Genomics Inc. is developing and marketing informatics tools for interpreting genetic information.

Seven Bridges’ business approach is to make its software tools accessible to clinicians and researchers with no expertise in bioinformatics, as well as to provide tools free of charge for designing custom analysis schemes.

Seven Bridges is part of the National Cancer Institute’s Cancer Genomics Cloud pilot program. This program is supporting the development of computing platforms for analyzing genomic data from major NCI projects, including the Cancer Genome Atlas. In October 2016, the NCI expanded Seven Bridges’ participation to include new data sources, including from additional cancer genome projects such as the Cancer Genome Characterization Initiative.

In September 2018, Seven Bridges formed a strategic partnership with E-Nios (Greece) covering the extraction of biomarker signatures from NGS and multi-omics data. This combined machine learning and physiology to automate part of the tedious process of interpreting potential biomarkers.

In June 2020, Seven Bridges joined the International Genomic Cancer Research Effort, an international alliance that seeks to link genomic cancer datasets from three groups: The Gabriella Miller Kids First Data Resource Center (Kids First DRC), Zero Childhood Cancer (Zero) and the Children’s Brain Tumor Tissue Consortium (CBTTC).

In January 2023, Seven Bridges was acquired by Summa Equity, a Stockholm-based private equity firm. Summa Equity merged Seven Bridges with genomic tech companies Pierian and UgenTec to form Velsera. This collaboration aims to advance precision medicine by overcoming research tool limitations and data silos. Bowen served as the exclusive M&A advisor to Seven Bridges.

Company's Business Segments

• Biomedical Data : The company specialises in Biomedical data platforms, namely Aria, GRAF, and RHEO. Aria- The platform is a centralised solution for high-throughput molecular and health data analysis. GRAF- The platform comprises bioinformatics workflows and tools for secondary analysis of next-generation sequencing (NGS) data based on a pan-genome graph reference. RHEO- The platform streamlines analysis workflows by minimizing the number of manual steps required to set up, run, and conclude an analysis.